Dulaglutide — EU research guide.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist fused to a modified antibody fragment (Fc region), which extends its half-life to roughly five days without needing a fatty-acid side chain like semaglutide.
What is Dulaglutide?
Structurally, dulaglutide links a modified GLP-1 peptide to an IgG4 Fc fragment, forming a large fusion protein rather than a fatty-acid-conjugated small peptide. This gives it a long half-life via the same recycling pathway antibodies use, enabling once-weekly dosing.
What does the research show?
The REWIND cardiovascular outcomes trial (2019) established dulaglutide's cardiovascular benefit in type 2 diabetes independent of weight loss, and it remains widely prescribed. Weight-loss effect is more modest than semaglutide or tirzepatide at equivalent tolerability, reflecting its diabetes-first development.
EU legal status
EMA-approved prescription medicine (Trulicity) for type 2 diabetes.
Molecular information
Pharmacokinetics
GLP-1 compounds across EU suppliers
COA-verified EU vendors · Updated monthly